대한본초학회지 (The Korea Journal of Herbology)

  • 제33권6호
  • /
  • Pages.61-70
  • /
  • 2018
  • /
  • 1229-1765(pISSN)
  • /
  • 2288-7199(eISSN)
대한본초학회 (The Korea Association of Herbology)
권호 표지
DOI QR코드

DOI QR Code

산사의 NAFLD 보호 효과 및 그 작용기전에 관한 연구

Non-alcoholic fatty liver protective effects, and studies on the mechanism of action of Crataegi Fructus

  • 김민철 (원광대학교 약학대학 한약학과, 원광한약연구소) ;
  • 공룡 (원광대학교 약학대학 한약학과, 원광한약연구소) ;
  • 한형선 (원광대학교 약학대학 한약학과, 원광한약연구소) ;
  • 강담희 (원광대학교 약학대학 한약학과, 원광한약연구소) ;
  • 이승진 (원광대학교 약학대학 한약학과, 원광한약연구소) ;
  • 이천천 (원광대학교 약학대학 한약학과, 원광한약연구소) ;
  • 왕서 (원광대학교 약학대학 한약학과, 원광한약연구소) ;
  • 권동렬 (원광대학교 약학대학 한약학과, 원광한약연구소) ;
  • 강옥화 (원광대학교 약학대학 한약학과, 원광한약연구소)
  • Kim, Min-Chul (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University) ;
  • Kong, Ryong (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University) ;
  • Han, Hyoung-Sun (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University) ;
  • Kang, Dam-hee (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University) ;
  • Lee, Seung-Jin (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University) ;
  • Lee, Cheon-Cheon (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University) ;
  • Wang, Seo (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University) ;
  • Kwon, Dong-Yeul (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University) ;
  • Kang, Ok-Hwa (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University)
  • 투고 : 2018.08.31
  • 심사 : 2018.11.25
  • 발행 : 2018.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives : Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of hepatic triglycerides (TG) that leads to inflammation and fibrosis. Crataegi Fructus ethanol extract (CE) is a korean traditional herb that used for digestive diseases. It has been investigated that CE has the effect that prevent hepatotoxicity caused by CCl4 or GaIN and regulate the inflammatory in several organs. However, a hypolipidemic effect of CF has not been reported. Methods : The purpose of this study is that examine the lipid accumulation inhibitory effect of CE on NAFLD. We checked the body and liver weight change of MCD-diet induced mice with/without administration of CE. The blood lipid levels of C57BL/6J mice were checked by biochemistry. Also we observed the liver histology of MCD-diet induced mice and investigate the molecular mechanisms in MCD-diet-induced NAFLD in C57BL/6J mice. Results : CE improved MCD-diet-induced lipid accumulation and TG and TC levels. Also, CE decreased hepatic lipogenesis such as SREBP-1, $C/EBP{\alpha}$, $PPAR{\gamma}$, ACC and FAS. Besides, we also found out that CE increased AMPK phosphorylation. These results indicated that CE has the same ability to activate AMPK and then reduce SREBP-1, and FAS expression, finally leading to inhibit hepatic lipogenesis and hepatic antioxidative ability. Conclusions : In this report, we found CE exerted a regulatory effect on lipid accumulation by decreasing lipogenesis in MCD-diet induced NAFLD model. Therefore, CE extract may be active in the prevention of fatty liver.

키워드

DHBCBU_2018_v33n6_61_f0001.tif 이미지

Figure 1. Body weight change of MCD-diet induced mice with/without treatment.

DHBCBU_2018_v33n6_61_f0002.tif 이미지

Figure 2. Liver weight changes of each experimental groups.

DHBCBU_2018_v33n6_61_f0003.tif 이미지

Figure 3. Effects of CE on blood lipid levels in C57BL/6J mice by biochemistry.

DHBCBU_2018_v33n6_61_f0004.tif 이미지

Figure 4. The effect of CE on the liver histology in MCD-diet-induced mice.

DHBCBU_2018_v33n6_61_f0005.tif 이미지

Figure 5. Effects of CE on MCD-diet induced liver function in C57BL/6J mice by biochemistry.

DHBCBU_2018_v33n6_61_f0006.tif 이미지

Figure 6. Effects of CE on hepatic lipid accumulation related protein and mRNA expression in liver tissue of experimental mice.

DHBCBU_2018_v33n6_61_f0007.tif 이미지

Figure 7. Effects of CE on lipogenesis related protein expression in liver tissue of experimental mice.

DHBCBU_2018_v33n6_61_f0008.tif 이미지

Figure 8. Effects of CE on AMPK phosphorylation in liver tissue of experimental mice.

Table 1. Sequences of oligonucleotide primers designed for PCR.

DHBCBU_2018_v33n6_61_t0001.tif 이미지

참고문헌

  1. Seo BI, Lee JH, Choi HY, Kwon DY and Boo YM. Herbology. Seoul : Younglimsa press. 2012:515-517.
  2. Son CW, Chae JK, Kim GW and Shin HM. Effects of Cragaegi Fructus on the Vascular Relaxation and Antioxidateive Status. Korean J of Oriental Medical Physiology & Pathology. 2002;16(1):67-71.
  3. Chon JW, Park JK, Lee MA, Jeong MR, Han JH, Park YK. Fermented Crataegi fructus vinegar improves lipid metabolism in ratsfed high fat diet. J Korean SocFood Sci Nutr. 2009;38(8):1024-1031. https://doi.org/10.3746/jkfn.2009.38.8.1024
  4. Tadic VM, Dobric S, Markovic GM, Dordevic SM, Arsic IA, Menkovic NR, and Stevic T. Antiinflammatory, gastroprotective, free radical scavenging and antimicrobial activities of hawthorn berries ethanol extract. J Agric Food Chem. 2008;56(17):7700-7709. https://doi.org/10.1021/jf801668c
  5. Kim KH, Lee SS, Baek JW, Lee SJ and Kim KH. Effect of Crataegii fructus on antioxidant capacity in D-galactose induced aging rats. Korean J Oriental Preventive Medical Soc. 2004;8:65-80.
  6. Seo BI. Preventive effects of water extracts form Crataegi fructuson hyperlipiderma and liverdamageinduced byalcohol. Korean J Herbology. 2005;20(1):35-43.
  7. Ko JS. Dermatology. Seoul:Soomoonsa Press. 2000;73.
  8. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hobbs HH Hepatology. 2004;40(6):1387-1395. https://doi.org/10.1002/hep.20466
  9. Bedogni G, Miglioli L, Masutti F, Castiglione A, Croce LS, Tiribelli C. Incidence and natural course of fatty liver in the general population: the Dionysos study. Bellentani S Hepatology. 2007; 46(5):1387-1391. https://doi.org/10.1002/hep.21827
  10. Cabanes JS, Chazarra S, Garcia-Carmona F. Kojic acid, a cosmetic skin whitening agent, is a slow binding inhibitor of catecholase activity of tyrosinase. J Pharm Pharmacol. 1994;46:982-985. https://doi.org/10.1111/j.2042-7158.1994.tb03253.x
  11. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrialdys functionin NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-2.
  12. Eberle D, Hegarty B, Bossard P, Ferre P and Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004;86(11):839-848. https://doi.org/10.1016/j.biochi.2004.09.018
  13. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. 1999;274:30028-30032. https://doi.org/10.1074/jbc.274.42.30028
  14. Winder WW, Hardie DG: AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol. 1999;277:E1-10.
  15. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell. Annu Rev Biochem. 1998;67:821-855. https://doi.org/10.1146/annurev.biochem.67.1.821
  16. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole -4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells. Eur J Biochem. 1995;229(2):558-565. https://doi.org/10.1111/j.1432-1033.1995.tb20498.x
  17. Louis NA, Witters LA. Glucose regulation of acetyl-CoA carboxylase in hepatoma and islet cells. J Biol Chem. 1992;267(4):2287-2293.
  18. Yang J, Maika S, Craddock L, King JA, Liu ZM. Chronic activation of AMP-activated protein kinase-alpha1 in liver leads to decreased adiposity in mice. Biochem Biophys Res Commun. 2008;370:248-253. https://doi.org/10.1016/j.bbrc.2008.03.094
  19. McGowan MW, Artiss JD, Strandbergh DR. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. J Clin Chem. 1983;29:538.
  20. Richmond W. Use of cholesterol oxidase for assay of total and free cholesterol in serum by continuous flow analysis. J Clin Chem. 1976;22:1579.
  21. Noma A, Nakayama KN, Kota M, Okabe H. Simultaneous determin ation of serum cholesterol in high and low density lipoprotein with use of heparin, Ca2+ and an anion exchange resin. J Clin Chem. 1978;24:1504.
  22. Bacon BR. Genetic, metabolic, and infiltrative diseases affecting the liver. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill. 2008;1980-1983.
  23. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231. https://doi.org/10.1056/NEJMra011775
  24. Suzuki A, Angulo P, Lymp J, Sauver J St, Muto A, Okada T, Lindor K. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005;41(1):64-71. https://doi.org/10.1002/hep.20543
  25. Yun JW, Cho YK. Clinical impact of non-alcoholic fatty liver disease on other medical diseases. Korean J Intern Med. 2009;76(1):25-29.
  26. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114(2):147-152. https://doi.org/10.1172/JCI22422
  27. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res. 2008;49(5):1068-1076. https://doi.org/10.1194/jlr.M800042-JLR200
  28. Brunt EM. Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis. 2002;6(2):399-420. https://doi.org/10.1016/S1089-3261(02)00002-8
  29. Leevy CM. Fatty liver. A study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine. 1962;41:249-276. https://doi.org/10.1097/00005792-196209000-00003
  30. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12:1106-1110. https://doi.org/10.1002/hep.1840120505
  31. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Path. 1989;20:594-598. https://doi.org/10.1016/0046-8177(89)90249-9
  32. Bacon BR, Faragvash MJ, Janny CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an espanded clinical entity. Gastroenterology. 1994;107:1103-1109. https://doi.org/10.1016/0016-5085(94)90235-6
  33. Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med. 2000;38:3-11.
  34. Farmer SR. Transcriptional control of adipocyte formation. Cell Metab. 2006;4(4):263-273. https://doi.org/10.1016/j.cmet.2006.07.001
  35. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8(10):774-785 https://doi.org/10.1038/nrm2249
  36. Viollet B, Guigas B, Leclerc J, Hebrard S, Lantier L, Mounier R, Andreelli F, Foretz M. AMP-activated protein kinasein there gulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf). 2009;196:81-98. https://doi.org/10.1111/j.1748-1716.2009.01970.x